Weekly Semaglutide Is Well-Tolerated in 3,505 Real-World Diabetes Patients Across Nine Countries

Among 3,505 T2D patients in real-world practice, once-weekly semaglutide showed 24.3% AE rate (mostly mild GI), 5.1% discontinuation rate, 0.5% serious ADRs, and 0.1% severe hypoglycemia — consistent with phase 3 RCT safety data.

Post hoc pooled analysis of nine SURE programme real-world studies (~30 weeks each). Collected safety data including AEs, serious AEs, hypoglycemic events, and treatment discontinuations. Analyzed for total population and subgroups based on baseline characteristics, co-medications, and prescriber specialty.

Real-world safety data is essential because clinical trial participants are carefully selected and monitored. Confirming semaglutide's safety across 3,505 unselected patients in routine practice gives prescribers and patients confidence that the drug is safe outside controlled settings.

As GLP-1 agonists are prescribed to millions of people globally, large-scale real-world safety surveillance becomes increasingly important. The SURE programme provides the most comprehensive real-world safety dataset for once-weekly semaglutide, complementing the controlled environment of the SUSTAIN clinical trials.

Observational studies lack the rigor of randomized trials. About 30 weeks of follow-up may miss longer-term safety signals. Subgroup analyses are hypothesis-generating, not definitive. Voluntary adverse event reporting may lead to underreporting.